Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. 1993

M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
Hypertension Clinic, Erasme University Hospital, Brussels, Belgium.

The acute and short-term responses to bisoprolol and to atenolol on systemic and renal hemodynamics and on ambulatory blood pressure (BP) were compared in a randomized double-blind cross-over study including 14 patients with mild to moderate essential hypertension. After a 4-week placebo period, the patients received either bisoprolol (10 mg once daily, o.d.) or atenolol (100 mg o.d.) for 4 weeks and were switched to the other drug after a new 4-week placebo period. Cardiac output (CO) was measured by Doppler echography, and renal blood flow (RBF) and glomerular filtration rate (GFR) were measured by constant infusion techniques using [123I]iodohippurate and [51Cr]EDTA, respectively. Bisoprolol and atenolol decreased diurnal and nocturnal blood pressure (BP). Both drugs decreased heart rate (HR) and BP both acutely and after 4 weeks. During short-term treatment, CO was maintained with bisoprolol but reduced by atenolol (by 17%). RBF decreased after the first drug intake (by 9 and 12%, respectively) but returned to its baseline value after 4 weeks, so that calculated renal vascular resistance (RVR) was reduced (by 12 and 15%, respectively). Overall, GFR was not affected by treatment. Bisoprolol and atenolol are effective antihypertensive agents that preserve renal hemodynamics during short-term treatment.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
July 1991, The American journal of cardiology,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
July 1988, American journal of hypertension,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
January 1987, Journal of cardiovascular pharmacology,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
January 1986, Acta cardiologica,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
July 1993, The American journal of cardiology,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
January 1987, European journal of clinical pharmacology,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
January 2007, Advances in therapy,
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
January 1983, Hypertension (Dallas, Tex. : 1979),
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
January 1984, Hypertension (Dallas, Tex. : 1979),
M Leeman, and P van de Borne, and F Collart, and G Vandenhoven, and L Peeters, and C Mélot, and J P Degaute
September 1962, Circulation,
Copied contents to your clipboard!